BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 11801702)

  • 1. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
    Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
    J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
    Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
    Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
    Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
    Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT.
    D'Souza MM; Sharma R; Jaimini A; Panwar P; Bansal A; Tripathi M; Varshney R; Pandey S; Mondal A
    Nucl Med Commun; 2012 Apr; 33(4):408-14. PubMed ID: 22301451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-acetate PET imaging of prostate cancer.
    Oyama N; Akino H; Kanamaru H; Suzuki Y; Muramoto S; Yonekura Y; Sadato N; Yamamoto K; Okada K
    J Nucl Med; 2002 Feb; 43(2):181-6. PubMed ID: 11850482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET.
    Etchebehere EC; Macapinlac HA; Gonen M; Humm K; Yeung HW; Akhurst T; Scher HI; Larson SM
    Q J Nucl Med; 2002 Jun; 46(2):122-30. PubMed ID: 12114875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
    Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H
    J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.
    Shiiba M; Ishihara K; Kimura G; Kuwako T; Yoshihara H; Sato H; Kondo Y; Tsuchiya S; Kumita S
    Ann Nucl Med; 2012 Feb; 26(2):138-45. PubMed ID: 22069194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
    Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer.
    Phan HT; Jager PL; Plukker JT; Wolffenbuttel BH; Dierckx RA; Links TP
    Nucl Med Commun; 2008 Aug; 29(8):711-6. PubMed ID: 18753824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
    Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
    World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of FDG-PET in clinical neuroendocrine prostate cancer.
    Spratt DE; Gavane S; Tarlinton L; Fareedy SB; Doran MG; Zelefsky MJ; Osborne JR
    Prostate; 2014 Aug; 74(11):1153-9. PubMed ID: 24913988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
    Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
    Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
    Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.